Sign in
Back
An Open-Label Safety Study of Lapatinib Plus Trastuzumab Plus Paclitaxel in First-Line HER2-Positive Metastatic Breast Cancer
Journal article   Open access  Peer reviewed

An Open-Label Safety Study of Lapatinib Plus Trastuzumab Plus Paclitaxel in First-Line HER2-Positive Metastatic Breast Cancer

Francisco J Esteva, Sandra X Franco, Maura K Hagan, Abenaa M Brewster, Robert A Somer, Will Williams, Allison M Florance, Simon Turner, Steven Stein and Alejandra Perez
The oncologist (Dayton, Ohio), Vol.18(6), pp.661-666
2013-06
DOI: https://doi.org/10.1634/theoncologist.2012-0129
PMCID: PMC4063391
PMID: 23697602

Abstract

Breast Cancer HER2 Lapatinib Paclitaxel Trastuzumab
Combining lapatinib and trastuzumab with taxane chemotherapy may offer clinical benefit to patients with cancer. Dose-limiting toxicities, safety, and tolerability of this combination was assessed. Of the triplet combinations tested, the cohort receiving 750 mg/day dose of lapatinib had the lowest incidence of diarrhea; therefore, this dose should be used in further studies on the treatment of metastatic breast cancer.
url
https://doi.org/10.1634/theoncologist.2012-0129View
Published (Version of record) Open

Metrics

8 Record Views
15 Times Cited - Web of Science

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types
Industry collaboration
Domestic collaboration
Citation topics
1 Clinical & Life Sciences
1.119 Breast Cancer Scanning
1.119.259 HER2
Web Of Science research areas
Oncology
ESI research areas
Clinical Medicine

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: InCites

Details